DRNA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 Dec 1970 @ 19:00):

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals...

Stats
Today's Volume	5.54M
Average Volume	3.03M
Market Cap	0.00
EPS	$-0.220 ( 2021-11-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.989 (2.59%)

Insider Trading

Date	Person	Action	Amount	type
2021-12-28	Koppel Adam	Sell	3 080 237	Common Stock
2021-12-28	Koppel Adam	Sell	3 333	Restricted Stock Units
2021-12-28	Koppel Adam	Sell	25 000	Director Stock Option (Right to Buy)
2021-12-28	Koppel Adam	Sell	25 000	Director Stock Option (Right to Buy)
2021-12-28	Koppel Adam	Sell	25 000	Director Stock Option (Right to Buy)

INSIDER POWER
0.00
Last 100 transactions
Buy: 12 087 \| Sell: 8 528 928

Volume Correlation

Long: 0.55 (weak)

Short: 0.93 (very strong)

Signal:(82.281) Expect same movement, but be aware

Dicerna Pharmaceuticals Correlation

10 Most Positive Correlations
ORTX	0.976
ASLN	0.972
ADMS	0.97
CSII	0.969
GRBK	0.962
WPRT	0.96
UNCY	0.959
NERV	0.959
NATI	0.958
NNOX	0.956

10 Most Negative Correlations
CPTN	-0.96
AADI	-0.958
CARA	-0.957
STIM	-0.956
PRAA	-0.955
BRKL	-0.953
VEON	-0.948
PEBK	-0.947
TCPC	-0.947
MDRX	-0.946

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Dicerna Pharmaceuticals Correlation - Currency/Commodity

-0.35
( neutral )

-0.32
( neutral )

0.07
( neutral )

0.21
( neutral )

-0.58
( weak negative )

0.68
( moderate )

Dicerna Pharmaceuticals Financials

Annual	2020
Revenue:	$164.31M
Gross Profit:	$164.31M (100.00 %)
EPS:	$-1.520

Q3	2021
Revenue:	$62.95M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.220

Q2	2021
Revenue:	$41.34M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.530

Q1	2021
Revenue:	$47.60M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.390

Financial Reports:

No articles found.

Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S.